The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression

Maxwell,Thressi; Chun,So-Young; Lee,Kyu-Shik; Kim,Soyoung; Nam,Kyung-Soo

doi:10.3892/ijo.2016.3825

The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression

Authors:
- Thressi Maxwell
- So-Young Chun
- Kyu-Shik Lee
- Soyoung Kim
- Kyung-Soo Nam
View Affiliations

Affiliations: Department of Pharmacology and Intractable Disease Research Center, School of Medicine, Dongguk University, Gyeongju-si 780-350, Republic of Korea
Published online on: December 29, 2016 https://doi.org/10.3892/ijo.2016.3825
Pages: 727-735

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arctigenin is a plant lignan extracted from Arctium lappa that has been shown to have estrogenic properties. In spite of the health benefits of phytoestrogens reducing the risk of osteoporosis, heart disease, and menopausal symptoms, its benefits against the risk of breast cancer have not been fully elucidated. Thus, we investigated the effects of arctigenin on metastasis of breast cancer using both estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cell lines to see if the effects are dependent on the status of ER expression. In ER-positive MCF-7 cells, arctigenin efficiently inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cell migration and invasion. The activity of crucial metastatic protease matrix metalloprotease (MMP)-9 in gelatin zymography was also efficiently decreased by arctigenin, as well as its mRNA expression. Notably, arctigenin exhibited similar anti-metastatic effects even in ER-negative MDA-MB-231 cells, suggesting that the anti-metastatic effects of arctigenin were not exerted via the ER. The upstream signaling pathways involved in the regulation of MMP-9 and urokinase plasminogen activator (uPA) were analyzed using western blotting. The activation of Akt, NF-κB and MAPK (ERK 1/2 and JNK 1/2) was found to be inhibited. Taken together, these data suggest that arctigenin confers anti-metastatic effects by inhibiting MMP-9 and uPA via the Akt, NF-κB and MAPK signaling pathways on breast cancer, regardless of ER expression. Therefore, we propose that the intake of arctigenin could be an effective supplement for breast cancer patients.

View Figures

View References

1	Gao H, Li G, Zhang J and Zeng J: Arctigenin: A lignan from Arctium lappa. Acta Crystallogr Sect E Struct Rep Online. 64:o15382008. View Article : Google Scholar : PubMed/NCBI
2	Kim Y, Hollenbaugh JA, Kim DH and Kim B: Novel PI3K/Akt inhibitors screened by the cytoprotective function of human immunodeficiency virus type 1 Tat. PLoS One. 6:e217812011. View Article : Google Scholar : PubMed/NCBI
3	Hayashi K, Narutaki K, Nagaoka Y, Hayashi T and Uesato S: Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol Pharm Bull. 33:1199–1205. 2010. View Article : Google Scholar : PubMed/NCBI
4	Swarup V, Ghosh J, Mishra MK and Basu A: Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother. 61:679–688. 2008. View Article : Google Scholar : PubMed/NCBI
5	Lee JY and Kim CJ: Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits type I–IV allergic inflammation and pro-inflammatory enzymes. Arch Pharm Res. 33:947–957. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kang HS, Lee JY and Kim CJ: Anti-inflammatory activity of arctigenin from Forsythiae Fructus. J Ethnopharmacol. 116:305–312. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yao X, Li G, Lü C, Xu H and Yin Z: Arctigenin promotes degradation of inducible nitric oxide synthase through CHIP-associated proteasome pathway and suppresses its enzyme activity. Int Immunopharmacol. 14:138–144. 2012. View Article : Google Scholar : PubMed/NCBI
8	Tsai WJ, Chang CT, Wang GJ, Lee TH, Chang SF, Lu SC and Kuo YC: Arctigenin from Arctium lappa inhibits interleukin-2 and interferon gene expression in primary human T lymphocytes. Chin Med. 6:122011. View Article : Google Scholar : PubMed/NCBI
9	Cho MK, Park JW, Jang YP, Kim YC and Kim SG: Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages. Int Immunopharmacol. 2:105–116. 2002. View Article : Google Scholar : PubMed/NCBI
10	Cho MK, Jang YP, Kim YC and Kim SG: Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: The role in TNF-alpha inhibition. Int Immunopharmacol. 4:1419–1429. 2004. View Article : Google Scholar : PubMed/NCBI
11	Jeong JB, Hong SC, Jeong HJ and Koo JS: Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells. Int Immunopharmacol. 11:1573–1577. 2011. View Article : Google Scholar : PubMed/NCBI
12	Susanti S, Iwasaki H, Itokazu Y, Nago M, Taira N, Saitoh S and Oku H: Tumor specific cytotoxicity of arctigenin isolated from herbal plant Arctium lappa L. J Nat Med. 66:614–621. 2012. View Article : Google Scholar : PubMed/NCBI
13	Awale S, Lu J, Kalauni SK, Kurashima Y, Tezuka Y, Kadota S and Esumi H: Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 66:1751–1757. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kim JY, Hwang JH, Cha MR, Yoon MY, Son ES, Tomida A, Ko B, Song SW, Shin-ya K, Hwang YI, et al: Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity. J Cell Physiol. 224:33–40. 2010.PubMed/NCBI
15	Zhang S, Li J, Song S, Li J, Tong R, Zang Z, Jiang Q and Cai L: Integrated in silico and experimental methods revealed that Arctigenin inhibited angiogenesis and HCT116 cell migration and invasion through regulating the H1F4A and wnt/β-catenin pathway. Mol Biosyst. 11:2878–2884. 2015. View Article : Google Scholar : PubMed/NCBI
16	Hausott B, Greger H and Marian B: Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol. 129:569–576. 2003. View Article : Google Scholar : PubMed/NCBI
17	Gu Y, Scheuer C, Feng D, Menger MD and Laschke MW: Inhibition of angiogenesis: A novel antitumor mechanism of the herbal compound arctigenin. Anticancer Drugs. 24:781–791. 2013. View Article : Google Scholar : PubMed/NCBI
18	Gu Y, Qi C, Sun X, Ma X, Zhang H, Hu L, Yuan J and Yu Q: Arctigenin preferentially induces tumor cell death under glucose deprivation by inhibiting cellular energy metabolism. Biochem Pharmacol. 84:468–476. 2012. View Article : Google Scholar : PubMed/NCBI
19	Susanti S, Iwasaki H, Inafuku M, Taira N and Oku H: Mechanism of arctigenin-mediated specific cytotoxicity against human lung adenocarcinoma cell lines. Phytomedicine. 21:39–46. 2013. View Article : Google Scholar : PubMed/NCBI
20	Yang S, Ma J, Xiao J, Lv X, Li X, Yang H, Liu Y, Feng S and Zhang Y: Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis. Anat Rec (Hoboken). 295:1260–1266. 2012. View Article : Google Scholar
21	Huang K, Li LA, Meng YG, You YQ, Fu XY and Song L: Arctigenin promotes apoptosis in ovarian cancer cells via the iNOS/NO/STAT3/survivin signalling. Basic Clin Pharmacol Toxicol. 115:507–511. 2014. View Article : Google Scholar : PubMed/NCBI
22	Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai EM and Hsu YL: Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic Biol Med. 67:159–170. 2014. View Article : Google Scholar
23	Jin JS, Lee JH and Hattori M: Ligand binding affinities of arctigenin and its demethylated metabolites to estrogen receptor alpha. Molecules. 18:1122–1127. 2013. View Article : Google Scholar : PubMed/NCBI
24	Matsumura A, Ghosh A, Pope GS and Darbre PD: Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol. 94:431–443. 2005. View Article : Google Scholar : PubMed/NCBI
25	Rice S and Whitehead SA: Phytoestrogens and breast cancer–promoters or protectors? Endocr Relat Cancer. 13:995–1015. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lephart ED: Modulation of aromatase by phytoestrogens. Enzyme Res. 2015:5946562015. View Article : Google Scholar
27	Whitehead SA and Lacey M: Phytoestrogens inhibit aromatase but not 17beta-hydroxysteroid dehydrogenase (HSD) type 1 in human granulosa-luteal cells: Evidence for FSH induction of 17beta-HSD. Hum Reprod. 18:487–494. 2003. View Article : Google Scholar : PubMed/NCBI
28	Low YL, Taylor JI, Grace PB, Dowsett M, Scollen S, Dunning AM, Mulligan AA, Welch AA, Luben RN, Khaw KT, et al: Phytoestrogen exposure correlation with plasma estradiol in postmenopausal women in European Prospective Investigation of Cancer and Nutrition-Norfolk may involve diet-gene interactions. Cancer Epidemiol Biomarkers Prev. 14:213–220. 2005.PubMed/NCBI
29	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar
30	Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG and Lee JS: Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 45:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
31	Straatman K: Wound healing assay. University of Leicester, College of Medicine, Biological Sciences and Psychology, Advanced Imaging Facilities; 2008
32	Loughlin DT and Artlett CM: Modification of collagen by 3-deoxyglucosone alters wound healing through differential regulation of p38 MAP kinase. PLoS One. 6:e186762011. View Article : Google Scholar : PubMed/NCBI
33	Lee K, Shin J, Kwon Y, Moon D and Nam K: Suppression of cancer progression and metastasis in HT-29 human colorectal adenocarcinomas by deep sea water. Biotechnol Bioprocess Eng. 18:194–200. 2013. View Article : Google Scholar
34	Mehner C, Hockla A, Miller E, Ran S, Radisky DC and Radisky ESR: Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 5:2736–2749. 2014. View Article : Google Scholar : PubMed/NCBI
35	Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V and Brünner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis. 14:297–307. 1996.PubMed/NCBI
36	Lungu G, Covaleda L, Mendes O, Martini-Stoica H and Stoica G: FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappaB and activating protein-1. Mol Carcinog. 47:424–435. 2008. View Article : Google Scholar
37	Moritani S, Nomura M, Takeda Y and Miyamoto K: Cytotoxic components of bardanae fructus (goboshi). Biol Pharm Bull. 19:1515–1517. 1996. View Article : Google Scholar : PubMed/NCBI
38	McCawley LJ and Matrisian LM: Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
39	Duffy MJ: The urokinase plasminogen activator system: Role in malignancy. Curr Pharm Des. 10:39–49. 2004. View Article : Google Scholar : PubMed/NCBI
40	Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE, Lynch M, Loganantharaj R, Trutschl M, Cvek U, et al: Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer. 8:272009. View Article : Google Scholar : PubMed/NCBI
41	Lilleholt LL, Johansen C, Arthur JS, Funding A, Bibby BM, Kragballe K and Iversen L: Role of p38 mitogen-activated protein kinase isoforms in murine skin inflammation induced by 12-O-tetradecanoylphorbol 13-acetate. Acta Derm Venereol. 91:271–278. 2011. View Article : Google Scholar : PubMed/NCBI